EP4698204A1 - Verfahren und zusammensetzungen zur behandlung von rnfl-verdünnung - Google Patents

Verfahren und zusammensetzungen zur behandlung von rnfl-verdünnung

Info

Publication number
EP4698204A1
EP4698204A1 EP24793478.9A EP24793478A EP4698204A1 EP 4698204 A1 EP4698204 A1 EP 4698204A1 EP 24793478 A EP24793478 A EP 24793478A EP 4698204 A1 EP4698204 A1 EP 4698204A1
Authority
EP
European Patent Office
Prior art keywords
peptide
thickness
composition
rnfl
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24793478.9A
Other languages
English (en)
French (fr)
Inventor
Andrew J. KOCAB
David N. Zacks
Constance I. CHANG
Lindsay M. PUSCAS
Stephanie C. WIETHOLTER
Lori Lynn HUANG
David A. ESPOSITO
Sushanta Mallick
Mitchell G. BRIGELL
David M. Kleinman
Jana Van De Goor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONL Therapeutics Inc
Original Assignee
ONL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONL Therapeutics Inc filed Critical ONL Therapeutics Inc
Publication of EP4698204A1 publication Critical patent/EP4698204A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24793478.9A 2023-04-19 2024-04-18 Verfahren und zusammensetzungen zur behandlung von rnfl-verdünnung Pending EP4698204A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363497128P 2023-04-19 2023-04-19
US202363497131P 2023-04-19 2023-04-19
US202363587386P 2023-10-02 2023-10-02
US202463631378P 2024-04-08 2024-04-08
PCT/US2024/025191 WO2024220669A1 (en) 2023-04-19 2024-04-18 Methods and compositions for treating rnfl thinning

Publications (1)

Publication Number Publication Date
EP4698204A1 true EP4698204A1 (de) 2026-02-25

Family

ID=93153350

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24793478.9A Pending EP4698204A1 (de) 2023-04-19 2024-04-18 Verfahren und zusammensetzungen zur behandlung von rnfl-verdünnung

Country Status (2)

Country Link
EP (1) EP4698204A1 (de)
WO (1) WO2024220669A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190201500A1 (en) * 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US10508134B2 (en) * 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
CN111132664A (zh) * 2017-08-20 2020-05-08 加州大学董事会 治疗青光眼的Wnt5a的调节

Also Published As

Publication number Publication date
WO2024220669A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
AU2021286278B2 (en) Methods for treating ocular diseases
US20200268768A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
JP2020019781A (ja) 抗ｉｌ−５抗体を投与するための方法
CN1829532A (zh) 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
AU2023390343A1 (en) Methods and compositions for improving visual function in ocular diseases and disorders
KR20150126345A (ko) 마이봄 기능부전의 치료제
TW202038966A (zh) 包含熊去氧膽酸之老花眼之治療或預防劑
EP2841104A1 (de) Pharmazeutische prostaglandin- und vasokonstriktorzusammensetzungen und verfahren zur verwendung
US20240156898A1 (en) Methods and compositions for treating ocular disorders and diseases
EP4698204A1 (de) Verfahren und zusammensetzungen zur behandlung von rnfl-verdünnung
US20240299488A1 (en) Methods and compositions for improving visual function in ocular diseases and disorders
US20250360123A1 (en) Methods and compositions for treating inherited retinal degeneration
WO2025184235A1 (en) Methods and compositions for treating glaucoma
EP4630029A1 (de) Verfahren und zusammensetzungen zur behandlung von augenläsionen
CN120569194A (zh) 治疗与中枢敏化相关的疼痛
CN117957010A (zh) 改善眼部疾病和病症中视功能的方法和组合物
KR20240060626A (ko) 드라이 아이의 예방 및/또는 치료를 위한 의약
ES2935917T3 (es) Composición farmacéutica que comprende polipéptidos
US20120329879A1 (en) Beta-adrenergic receptor agonists and uses thereof
JP2022120834A (ja) シェーグレン症候群治療剤
JP2023043139A (ja) ドライアイの予防及び／又は治療剤
Li et al. Evaluation of Single Dose Safety, PK, and PD of A Novel Human Anti-IL6 Monoclonal antibody PF-04236921 in Phase I Healthy Volunteers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR